- Home
- ARBK vs TPST Comparison
ARBK vs TPST Comparison
Compare ARBK & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARBK | TPST |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 11.3M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | ARBK | TPST |
|---|---|---|
| Price | $2.93 | $2.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 23.2K | ★ 54.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | $183.90 | N/A |
| Revenue Next Year | $26.78 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $0.60 |
| 52 Week High | $28.64 | $12.22 |
Technical Indicators
Market Signals| Indicator | ARBK | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 39.33 |
| Support Level | $2.63 | $2.16 |
| Resistance Level | $5.39 | $2.52 |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 44.12 | 40.51 |
Price Performance
Historical ComparisonAbout ARBK Argo Blockchain plc
Argo Blockchain PLC is a blockchain technology company focused on the large-scale mining of Bitcoin. It mines bitcoin using purpose-built computers (or mining machines) to solve complex cryptographic algorithms on the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company acquires and deploys mining technology solutions in North American facilities that utilize predominantly renewable and inexpensive electricity.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.